Price Action Don’t Lie: Time to Buy Eagle Pharmaceuticals Inc After Today’s Significant Decline?

Price Action Don't Lie: Time to Buy Eagle Pharmaceuticals Inc After Today's Significant Decline?

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 240,130 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 5.74% since March 3, 2016 and is uptrending. It has underperformed by 2.60% the S&P500.
The move comes after 7 months negative chart setup for the $1.01B company. It was reported on Oct, 6 by We have $61.62 PT which if reached, will make NASDAQ:EGRX worth $50.50M less.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on November, 9. They expect $0.84 earnings per share, up 229.23% or $1.49 from last year’s $-0.65 per share. EGRX’s profit will be $13.08M for 19.30 P/E if the $0.84 EPS becomes a reality. After $0.80 actual earnings per share reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 3 analysts covering Eagle Pharma (NASDAQ:EGRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Eagle Pharma has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Mizuho downgraded the shares of EGRX in a report on Monday, June 20 to “Neutral” rating. The firm has “Buy” rating given on Wednesday, December 9 by Mizuho. RBC Capital Markets maintained Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Tuesday, May 10 with “Outperform” rating. The company was maintained on Wednesday, July 29 by Piper Jaffray. Mizuho maintained it with “Buy” rating and $81 target price in Friday, February 26 report.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”

More notable recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: which released: “Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today” on June 10, 2016, also with their article: “Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August” published on September 09, 2016, published: “Eagle Pharmaceuticals Achieves Milestone to Receive $15 Million Payment for …” on December 08, 2015. More interesting news about Eagle Pharmaceuticals Inc (NASDAQ:EGRX) were released by: and their article: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle …” published on June 06, 2016 as well as‘s news article titled: “Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka …” with publication date: May 09, 2016.

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment